Odronextamab

Legal statusLegal status IdentifiersCAS NumberDrugBankUNIIKEGGChemical and physical dataFormulaC₆₄₅₈H₉₉₅₀N₁₇₂₈O₂₀₂₀S₄₆Molar mass145593.47 g·mol⁻¹

Odronextamab, sold under the brand name Ordspono, is a CD20 x CD3 bispecific monoclonal antibody that is used for the treatment of follicular lymphoma or diffuse large B-cell lymphoma.^[1][2] It was developed by Regeneron Pharmaceuticals.^[1]

Odronextamab is indicated for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy;^[1] and for the treatment of adults with relapsed or refractory diffuse large B‑cell lymphoma after two or more lines of systemic therapy.^[1]

The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia, anemia, thrombocytopenia and diarrhea.^[1]

In June 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Ordspono, intended for the treatment of follicular lymphoma and diffuse large B-cell lymphoma.^[1][3] The applicant for this medicinal product is Regeneron Ireland Designated Activity Company.^[1] Odronextamab was approved for medical use in the European Union in August 2024.^[1][2][4]

Odronextamab is the international nonproprietary name.^[5]

• Bannerji, Rajat; Allan, John N.; Arnason, Jon E.; Brown, Jennifer R.; Advani, Ranjana; Ansell, Stephen M.; et al. (November 2020). "Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy". Blood. 136 (Supplement 1): 42–43. doi:10.1182/blood-2020-136659. S2CID 228809346.
• Bannerji, Rajat; Arnason, Jon E; Advani, Ranjana H; Brown, Jennifer R; Allan, John N; Ansell, S tephen M; et al. (May 2022). "Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial". The Lancet Haematology. 9 (5): e327–e339. doi:10.1016/S2352-3026(22)00072-2. PMC 10681157. PMID 35366963.
• Kim, Tae Min; Alonso, Arancha; Prince, Miles; Taszner, Michal; Cho, Seok-Goo; Stevens, Don A.; et al. (November 2020). "A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma". Blood. 136 (Supplement 1): 28–29. doi:10.1182/blood-2020-136344. S2CID 228841832.
• Wei, Joyce; Montalvo-Ortiz, Welby; Yu, Lola; Krasco, Amanda; Olson, Kara; Rizvi, Sahar; et al. (November 2022). "CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models". Science Translational Medicine. 14 (670): eabn1082. doi:10.1126/scitranslmed.abn1082. PMID 36350988. S2CID 253445866.